Collection of Blood From Patients With Prostate Cancer
| Status: | Recruiting |
|---|---|
| Conditions: | Prostate Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 100 |
| Updated: | 4/6/2019 |
| Start Date: | March 1, 2007 |
| Contact: | Paula A Carter, R.N. |
| Email: | pcartera@mail.nih.gov |
| Phone: | (240) 858-3191 |
Background:
- It is not fully understood why prostate cancer in some men becomes androgen-independent
(no longer responds to anti-androgen medication), but genetics likely plays an important
role.
- Genes contain the hereditary information that is passed down from parents to children.
Although everyone has the same set of genes, individuals can have different forms of the
same gene.
- Differences in genes may explain, at least in part, why some people develop a more
aggressive form of prostate cancer than others.
Objectives:
-To obtain blood samples from patients with prostate cancer to try to identify gene
differences associated with progression to the androgen independent state.
Eligibility:
-All patients participating in NCI prostate cancer protocols.
Design:
- Patients with prostate cancer are evaluated in the NCI s Medical Oncology Clinic.
- Blood samples are collected at the initial visit or at follow-up visits.
- DNA (genetic material) and white blood cells are extracted from these samples to be used
for genotyping and establishment of cell lines.
- Gene variations are correlated with prostate cancer prognosis and prognostic indicators.
- It is not fully understood why prostate cancer in some men becomes androgen-independent
(no longer responds to anti-androgen medication), but genetics likely plays an important
role.
- Genes contain the hereditary information that is passed down from parents to children.
Although everyone has the same set of genes, individuals can have different forms of the
same gene.
- Differences in genes may explain, at least in part, why some people develop a more
aggressive form of prostate cancer than others.
Objectives:
-To obtain blood samples from patients with prostate cancer to try to identify gene
differences associated with progression to the androgen independent state.
Eligibility:
-All patients participating in NCI prostate cancer protocols.
Design:
- Patients with prostate cancer are evaluated in the NCI s Medical Oncology Clinic.
- Blood samples are collected at the initial visit or at follow-up visits.
- DNA (genetic material) and white blood cells are extracted from these samples to be used
for genotyping and establishment of cell lines.
- Gene variations are correlated with prostate cancer prognosis and prognostic indicators.
Objectives:
To obtain blood samples from patients with prostate cancer for genotyping analyses.
Eligibility:
All patients seen in the NCI prostate cancer clinic are eligible.
Design:
Patients with a prior diagnosis of prostate cancer will be evaluated in the GMB Clinic, NCI.
Blood samples may be collected at the initial visit or at follow-up visits. Genomic DNA and
white blood cells will each be extracted from these samples to be utilized for genotyping and
establishment of individual cell lines. Genetic variance will be correlated with prostate
cancer prognosis (i.e. time from diagnosis to death) and prognostic indicators (i.e.
histological tumor grade). Healthy controls will not be compared and no correlations will be
made with prostate cancer susceptibility.
To obtain blood samples from patients with prostate cancer for genotyping analyses.
Eligibility:
All patients seen in the NCI prostate cancer clinic are eligible.
Design:
Patients with a prior diagnosis of prostate cancer will be evaluated in the GMB Clinic, NCI.
Blood samples may be collected at the initial visit or at follow-up visits. Genomic DNA and
white blood cells will each be extracted from these samples to be utilized for genotyping and
establishment of individual cell lines. Genetic variance will be correlated with prostate
cancer prognosis (i.e. time from diagnosis to death) and prognostic indicators (i.e.
histological tumor grade). Healthy controls will not be compared and no correlations will be
made with prostate cancer susceptibility.
- INCLUSION CRITERIA:
Patients 18 years of age and older are eligible.
Patients with a diagnosis of prostate cancer are eligible.
EXCLUSION CRITERIA:
Children are not eligible.
We found this trial at
1
site
9000 Rockville Pike
Bethesda, Maryland 20892
Bethesda, Maryland 20892
Phone: (888) NCI-1937
Click here to add this to my saved trials
